Drug Shortage Analysis Puts FDA At Loggerheads With GAO
This article was originally published in The Pink Sheet Daily
GAO says ongoing drug shortages are increasing, but FDA says they are flattening; contrasting definitions of “shortage” produce the disparate results.
You may also be interested in...
GAO's 'high risk' report lowers FDA grade for its drug shortage action plans, saying efforts have not been sustained.
But agency's policy changes have failed to ameliorate ongoing shortages, GAO finds.
In its latest biosimilar trends report, Amgen makes the case for purchasing biosimilars from a company with a track record for quality biologics manufacturing – presumably, one such as its own.